Patient with inoperable pheochromocytoma

J 2015

Patient with inoperable pheochromocytoma

BRANČÍKOVÁ, Dagmar, Zdeněk MECHL, Zdeněk ADAM, Eva JANDÁKOVÁ, Zdeněk PAVLOVSKÝ et. al.

Základní údaje

Originální název

Patient with inoperable pheochromocytoma

Autoři

BRANČÍKOVÁ, Dagmar (203 Česká republika, garant, domácí), Zdeněk MECHL (203 Česká republika), Zdeněk ADAM (203 Česká republika, domácí), Eva JANDÁKOVÁ (203 Česká republika, domácí), Zdeněk PAVLOVSKÝ (203 Česká republika, domácí), Vlastimil VÁLEK (203 Česká republika, domácí) a Tomáš ANDRAŠINA (703 Slovensko, domácí)

Vydání

Current Oncology, Toronto, Multimed INC. 2015, 1198-0052

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Kanada

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.829

Kód RIV

RIV/00216224:14110/15:00083405

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3747/co.22.2324

UT WoS

000356976100010

Klíčová slova anglicky

Pheochromocytoma; chemoembolization; lanreotide

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 13. 1. 2016 14:16, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Malignant pheochromocytoma is a tumour with a very low incidence that occurs sporadically or in the presence of multiple endocrine neoplasia. We present the case of a woman with a sporadic occurrence of pheochromocytoma diagnosed in the phase of multiple dissemination in the abdominal cavity and overexpressing adrenaline, noradrenaline, and dopamine. Local transarterial chemoembolization and systemic treatment with lanreotide resulted in a very good response, a decrease in the production of catecholamines for 12 months and a partial decrease for another 8 months, with stabilization of disease determined by imaging. Systemic treatment with tegafur resulted in disease stabilization lasting 50 months, after which the drug was discontinued because of adverse effects. Maintenance therapy with lanreotide continues, and no disease progression has been observed for 4 months. The treatment algorithm for such patients is multidisciplinary and must always take into account the current scope of the disease, intercurrence, and the general condition of the patient.

Citovat

BRANČÍKOVÁ, Dagmar, Zdeněk MECHL, Zdeněk ADAM, Eva JANDÁKOVÁ, Zdeněk PAVLOVSKÝ, Vlastimil VÁLEK a Tomáš ANDRAŠINA. Patient with inoperable pheochromocytoma. Current Oncology. Toronto: Multimed INC., 2015, roč. 22, č. 3, s. "E216"-"E219", 4 s. ISSN 1198-0052. Dostupné z: https://dx.doi.org/10.3747/co.22.2324.

@article{1306351,
   author = {Brančíková, Dagmar and Mechl, Zdeněk and Adam, Zdeněk and Jandáková, Eva and Pavlovský, Zdeněk and Válek, Vlastimil and Andrašina, Tomáš},
   article_location = {Toronto},
   article_number = {3},
   doi = {http://dx.doi.org/10.3747/co.22.2324},
   keywords = {Pheochromocytoma; chemoembolization; lanreotide},
   language = {eng},
   issn = {1198-0052},
   journal = {Current Oncology},
   title = {Patient with inoperable pheochromocytoma},
   volume = {22},
   year = {2015}
}

TY  - JOUR
ID  - 1306351
AU  - Brančíková, Dagmar - Mechl, Zdeněk - Adam, Zdeněk - Jandáková, Eva - Pavlovský, Zdeněk - Válek, Vlastimil - Andrašina, Tomáš
PY  - 2015
TI  - Patient with inoperable pheochromocytoma
JF  - Current Oncology
VL  - 22
IS  - 3
SP  - "E216"-"E219"
EP  - "E216"-"E219"
PB  - Multimed INC.
SN  - 11980052
KW  - Pheochromocytoma
KW  - chemoembolization
KW  - lanreotide
N2  - Malignant pheochromocytoma is a tumour with a very low incidence that occurs sporadically or in the presence of multiple endocrine neoplasia. We present the case of a woman with a sporadic occurrence of pheochromocytoma diagnosed in the phase of multiple dissemination in the abdominal cavity and overexpressing adrenaline, noradrenaline, and dopamine. Local transarterial chemoembolization and systemic treatment with lanreotide resulted in a very good response, a decrease in the production of catecholamines for 12 months and a partial decrease for another 8 months, with stabilization of disease determined by imaging. Systemic treatment with tegafur resulted in disease stabilization lasting 50 months, after which the drug was discontinued because of adverse effects. Maintenance therapy with lanreotide continues, and no disease progression has been observed for 4 months. The treatment algorithm for such patients is multidisciplinary and must always take into account the current scope of the disease, intercurrence, and the general condition of the patient.
ER  -

BRANČÍKOVÁ, Dagmar, Zdeněk MECHL, Zdeněk ADAM, Eva JANDÁKOVÁ, Zdeněk PAVLOVSKÝ, Vlastimil VÁLEK a Tomáš ANDRAŠINA. Patient with inoperable pheochromocytoma. \textit{Current Oncology}. Toronto: Multimed INC., 2015, roč.~22, č.~3, s.~''E216''-''E219'', 4 s. ISSN~1198-0052. Dostupné z: https://dx.doi.org/10.3747/co.22.2324.

Podrobný výpis o publikaci